Pre-made Albiglutide benchmark antibody (Peptide Protein fusion , anti-GLP1R therapeutic antibody, Anti-GLP-1-R/GLP-1R Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes.
As of 217 it is unclear if it affects a person’s risk of death.[1] GSK has announced that it intends to withdraw the drug from the worldwide market by July 218 for economic reasons.